Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/28/2025 | $7.00 | Outperform | Leerink Partners |
| 4/1/2025 | $6.00 | Buy | Jefferies |
| 11/29/2023 | $4.00 | Buy | BTIG Research |
| 8/28/2023 | $3.75 | Neutral → Buy | H.C. Wainwright |
| 5/31/2023 | $2.00 → $4.00 | Neutral → Overweight | Piper Sandler |
| 3/31/2022 | $10.00 → $2.00 | Buy → Neutral | H.C. Wainwright |
| 3/31/2022 | Buy → Hold | Needham | |
| 3/31/2022 | $6.00 → $2.00 | Buy → Neutral | Mizuho |
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 8, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time. A live webcast of the conference ca
Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 million Cash resources and cash from operations expected to fund current operating plan for at least two years Akebia to Host Conference Call at 8:00 a.m. ET on March 13, 2025 CAMBRIDGE, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full year ended December 31, 2024 and recent business highlights. As previously announced, Vafseo® (vadadustat) shipments to customers began Januar
CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 13, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, March 13, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time. A live web
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia Executive Management will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 5 at 8:45 AM EDT. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference. The Jefferies Global Healthcare Conference will take place June 3-5, 2025, in New York City. About Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmace
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it will present data at the 62nd European Renal Association (ERA) Congress on June 4-7, 2025, both virtually and live in Vienna. Akebia-supported presentations at ERA Congress 2025: A Win-Ratio Analysis of the Cardiovascular Safety of Vadadustat in Patients with CKD-Related Anemia Undergoing DialysisFree Communication 15: Novel CKD Treatments Beyond the PillarsAbstract No. 3359Dr. Glenn Chertow to present on Friday, June 6 at 8:15 am CEST Vadadustat Combination with Ferric Citra
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, and Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20 at 2:30 PM EDT. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference. The H.C. Wainwright BioConnect Investor Conference will take place on May 20, 2025, at the Nasdaq Headquarters in N
CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeut
CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors. Frieson currently serves as the Chief Operating Officer of Children's Healthcare of Atlanta (CHOA), a non-profit corporation whose mission focuses on bettering all aspects of children's healthcare. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt
Leerink Partners initiated coverage of Akebia Therapeutics with a rating of Outperform and set a new price target of $7.00
Jefferies initiated coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $6.00
BTIG Research resumed coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $4.00
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity
10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)
8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)
SCHEDULE 13G - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)